Diabetes - Pipeline Review, H2 2013

Global Markets Direct
September 20, 2013
427 Pages - SKU: GMD5121498
Diabetes - Pipeline Review, H2 2013

Diabetes - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Diabetes - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Diabetes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetes. Diabetes - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Diabetes.
  • A review of the Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Diabetes pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Diabetes.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Diabetes pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


Additional Information

Companies Mentioned

Bristol-Myers Squibb Company
Baxter International Inc.
Sanofi-Aventis
Eli Lilly and Company
Athersys, Inc.
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
Takeda Pharmaceutical Company Limited

More Drug Discovery reports by Global Markets Direct

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2014 by Global Markets Direct
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 ...
Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2014 by Global Markets Direct
Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2014’, provides an overview of the Pseudomonas Aeruginosa ...
Ischemic Cerebral Stroke - Pipeline Review, H2 2014 by Global Markets Direct
Ischemic Cerebral Stroke - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Ischemic Cerebral Stroke - Pipeline Review, H2 2014’, provides an overview of the Ischemic Cerebral ...
Endothelial Dysfunction - Pipeline Review, H2 2014 by Global Markets Direct
Endothelial Dysfunction - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Endothelial Dysfunction - Pipeline Review, H2 2014’, provides an overview of the Endothelial Dysfunction’s therapeutic pipeline.This ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 2,000  
    Site License  USD 4,000  
    Global Site License  USD 6,000  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!